### **Overview** P I Industries Ltd (PIIL), founded in 1946, has evolved from an Indian agri-sciences pioneer into a globally recognized **integrated life sciences company**, operating across agrochemicals, pharmaceuticals, biologicals, electronic & specialty chemicals, and custom research & manufacturing. It is one of the few Asian companies with a **fully integrated value chain — from discovery and R&D to manufacturing, distribution, and customer engagement** — positioning it at the intersection of scientific innovation, sustainability, and high-quality revenue growth. --- ### **Strategic Transformation & Vision** PI Industries is in the midst of a **strategic transformation**, transitioning from a dominant agrochemical player into a **diversified global life sciences leader**. Its long-term vision, as of Aug 2025, is to: - **Become a global technology leader in agricultural biologicals**. - **Establish a differentiated position in the pharmaceutical CRDMO (Contract Research, Development and Manufacturing Organization) space**. - **Expand into high-value specialty and electronic chemicals**, benefiting from global supply chain realignment. - Target a **10x market opportunity**, moving beyond its $1B+ agrochemical base into a $100B+ life sciences ecosystem. The company's core philosophy centers on **science-driven innovation, green chemistry, operational excellence, and sustainability**, underpinned by a **non-conflicting business model built on strong IP protection and trust** with global innovators. --- ### **Growth Engines & Strategic Focus Areas (FY2025–26)** In the current period, PI is focusing growth across **five key pillars**: #### 1. **Agri-Sciences (Core Strength)** - Leading agrochemical distributor in India with **significant market share in key crops**. - Operates a **pan-India network of over 15,000 distributors and 100,000 retail points**, reaching over 3 million farmers. - Focus on **branded, premium, and specialty products** to counter generic pricing pressure. - Commercializing **proprietary New Chemical Entities (NCEs)** like the groundbreaking **PIOXANILIPROLE**, India's first homegrown insecticide to receive **ISO approval**. - PIOXANILIPROLE is in **Phase-3 trials** with major markets (India, US, Brazil) targeted — marking a **first-of-its-kind Indian innovation in global agrochemicals**. - Strong domestic pipeline: Over **20+ new products in development/registration**, with **6 new agri brands launched in FY24-25** (e.g., Pressedo®, Osheen Ultra®, Dorito®). - Domestic brands like **Awkira, Eketsu, and Brofreya** have gained leadership in wheat, rice, and horticulture segments. #### 2. **Biologicals (Fastest-Growing Segment)** - A **key future growth driver**, with biologicals revenue growing at **~20–25% YoY** and projected to scale **5x over the next 5 years**. - Portfolio includes **15+ biological products**, with **strong growth in bio-pesticides, bio-fertilizers, and biostimulants**. - Core strengths: - **PREtec technology platform** (derived from natural proteins/peptides) acquired via **Plant Health Care (PHC)**, enhancing plant immunity, yield, and stress tolerance. - **Harpin αβ and peptide-based products** with proven grower adoption in US, Brazil, Mexico, UK, and EU. - R&D hubs in **Seattle (USA), Hyderabad, and Udaipur (India)**. - Manufacturing through high-efficiency **European partners** and a **state-of-the-art R&D center under construction in Hyderabad**. - PHC acquisition added **patented IP, 3 commercialized products, and strong global presence** — accelerating PI’s entry into the **$10B global biologicals market (projected to double by 2030)**. #### 3. **Pharma CRDMO (Contract Research, Development & Manufacturing Organization)** - Operated under **PI Health Sciences (PIHS)**, a wholly-owned subsidiary. - A **$100B+ addressable market** entry via strategic acquisitions and integrated platform build-up: - Acquired **Archimica SpA (Italy)**: GMP-certified API/CDMO with 24 US DMFs, serving 60+ global clients. - Acquired **Therachem Research Medilab (India & US)**: Specialized in medicinal chemistry for rare diseases. - Acquired **Solis Pharmachem (India)**: Adds niche manufacturing capability. - **Integrated CRDMO platform** with facilities in **Hyderabad (India), Lodi (Italy), and Jaipur**, featuring: - **GMP Kilo-labs**, **R&D flow labs**, and **process safety units**. - Capabilities in **peptides, antibody-drug conjugates (ADCs), large molecules, HP-PI, OEB 5, and oligonucleotides**. - Achieved **186% YoY revenue growth** in the latest pharma segment quarter. - Targeting **3x revenue growth in 3–4 years** by serving large pharma and biotech innovators. #### 4. **Electronic & Specialty Chemicals** - Diversifying beyond agri into **high-value fine chemicals**, particularly electronic chemicals. - Over **50% of new CSM inquiries now from non-agrochemical sectors** — signaling a successful pivot. - Leverages expertise in **complex and hazardous chemistry (130+ unit processes), flow chemistry, and biocatalysis**. - Benefits from **global supply chain realignment (China+1)** and demand for high-purity, sustainable chemistries. - Successfully **commercialized electronic chemicals** and aims for **~one-third of future molecule launches from non-agro segments**. #### 5. **Sustainability-Driven Innovation** - Among **top 3% ESG-rated chemical companies globally**, included in **S&P Global Sustainability Yearbook 2025** for two consecutive years. - Focus on **green chemistry, biocatalysis, flow chemistry, digital integration, and waste reduction**. - 99% of raw materials sourced sustainably; **100% recycled paper packaging**. - Investments in **automation, emissions control, energy efficiency, and HCl recycling systems**. - Pioneered **biocatalysis** and microbial waste treatment technologies. --- ### **Research & Development (R&D) & Innovation Infrastructure** - **700+ scientists** across four R&D centers (Udaipur, Hyderabad, Jaipur, Lodi, Italy, and Seattle). - Over **200+ PhDs**; 44 patents filed in FY24-25 alone; **220+ total patents** cumulatively. - State-of-the-art labs with **NABL, ISO/IEC 17025, GLP, and OECD certifications**. - Advanced capabilities: **UPLC-CAD, ICP-OES, pXRD, RC1mx, ARC**, and digital batch records. - AI-driven development tools, **Golden Batch System**, and **electronic data management** enhance decision-making. - Key innovations: - **PIOXANILIPROLE**: First ISO-approved Indian insecticide; targets Lepidopteran pests with multi-billion market potential. - **In-house development of hydrogenation catalysts, phase transfer catalysts, and chlorine-based synthesis routes** — enhancing cost efficiency and sustainability. - Proprietary **PREtec**, **Harpin**, and **peptide-based biologicals**. --- ### **Manufacturing & Digital Capabilities** - **5 manufacturing locations** with **15+ Multi-Purpose Plants (MPPs)**, fully automated with **Distributed Control Systems (DCS)**. - Facilities in **Panoli and Jambusar (Gujarat)**, with **high-pressure reaction units** and **specialized high-hazard capabilities**. - Digital Manufacturing Technologies (DMT) used for real-time monitoring and optimization. - Ongoing Capex: Two **new MPPs under construction**; Kilo-lab in **Lodi, Italy, commissioned**. - Capex spend: ~₹130 crore in Pharma (FY24-25); total Capex planned at ₹100–125 crore. - Global sourcing strategy with **74% domestic input sourcing** — reducing reliance on China. --- ### **Business Model & Commercial Strategy** - **Dual Revenue Model**: - **Domestic Agri Brands**: Branded crop protection (insecticides, fungicides, herbicides, biologicals) distributed via 15,000+ partners. - **CSM Exports**: Custom synthesis and manufacturing for **global innovators**, primarily patent-protected, early-stage molecules. - **Non-conflicting IP model** has sustained **50+ year partnerships** with over **20 global innovators**. - Services include: - R&D, formulation, regulatory registration, manufacturing, distribution, co-marketing, and application services. - CRO, CDMO, API, and intermediates synthesis. - Global footprint: **Presence in >30 countries**, with offices in **Japan (Biz Dev), China (Sourcing), Germany (Knowledge Management), and the US (R&D via Seattle)**. --- ### **Inorganic Growth & Strategic Acquisitions** - Key acquisitions: - **Plant Health Care (PHC) Ltd (2024)**: Bolstered global biologicals business with peptide tech and US/EU/LATAM distribution. - **Archimica, Therachem, and Solis Pharmachem (2023)**: Formed the foundation of PI Health Sciences (PIHS). - **Jivagro Limited (2019)**: Horticulture-focused subsidiary now a key player with >60 brands. - Evaluation of **M&A opportunities** in pharma, specialty chemicals, biochemicals — targeting assets with **complementary technologies, IP, and customer bases**. - Raised **~₹2,000 crore via QIP** — part of strategic capital allocation for diversification. --- ### **Key Competitive Advantages** 1. **End-to-end integration** — from molecule discovery to last-mile delivery. 2. **Technology differentiation** — in complex chemistry, automation, digital platforms, and biologicals. 3. **Strong IP culture** — respected by global innovators. 4. **Diversified growth engines** — reducing reliance on any single segment. 5. **Talent-driven leadership** — with global veterans in pharma and biologicals. 6. **Resilient balance sheet** — supporting organic and inorganic expansion. ---